

Electronic Acknowledgement Receipt

EFS ID:	6285044
Application Number:	10539385
International Application Number:	
Confirmation Number:	4857
Title of Invention:	BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
First Named Inventor/Applicant Name:	Sanjeet Sehmi
Customer Number:	23347
Filer:	Duke M. Fitch/Mary Fenerty
Filer Authorized By:	Duke M. Fitch
Attorney Docket Number:	P33159USW
Receipt Date:	19-OCT-2009
Filing Date:	16-JUN-2005
Time Stamp:	14:43:13
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	807
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE_Transmittal.pdf	95164 cc916da110b44d31e29d27a5e41381cc384884	no	1

Warnings:

This is not a USPTO supplied RCE SB30 form.

Information:

2		Information_Disclosure_Statement_and_1449.pdf	263722 4a310d46f909d6c0f0a0f07264d181d1c21 63/08	yes	3
Multipart Description/PDF files in .zip description					
Document Description		Start		End	
Transmittal Letter		1		1	
Information Disclosure Statement (IDS) Filed (SB/08)		2		3	

Warnings:

Information:

3	Foreign Reference	1WO9605194A1.pdf	5789360 c53974598d3ca9870a0ddd811a7a0897a a8cd	no	154
---	-------------------	------------------	--	----	-----

Warnings:

Information:

4	Foreign Reference	2WO2004058682A1_part_1.pdf	16171064 a52891e998a0327d67d765726b151f3dec2 04fb6	no	491
---	-------------------	----------------------------	--	----	-----

Warnings:

Information:

5	Foreign Reference	2WO2004058682A1_part_2.pdf	12668023 81a029559353b744a6a61932e11ad407e1c 5d996	no	491
---	-------------------	----------------------------	--	----	-----

Warnings:

Information:

6	Foreign Reference	3WO2005014479A2.pdf	1168787 D959c1e8380782774830059e5f8942ed1d 26d1	no	28
---	-------------------	---------------------	---	----	----

Warnings:

Information:

7	Foreign Reference	4WO2005039591A1.pdf	2113209 644443d66d1a917a5a4cc0f62213b295e 6dc	no	43
Warnings:					
Information:					
8	Foreign Reference	5WO2005058328A1.pdf	2938402 6911c61919f5ed0f3609802d5598fbcb3c7f 0176	no	66
Warnings:					
Information:					
9	Foreign Reference	6CA2197789.pdf	5373828 0e0f6d1a6196d8795e6c5x8fb634c6a6f02 08	no	151
Warnings:					
Information:					
10	Foreign Reference	7EP0612741B1.pdf	3860319 2a8b6d07264b32d1fc495f69a3b6d1897 1fca	no	95
Warnings:					
Information:					
11	NPL Documents	8Medhurst_BiochemPharmacol_2007.pdf	592134 f0e11919eb4433a6379201b4798eb3af c559	no	13
Warnings:					
Information:					
12	NPL Documents	9Southam_Psychoph_2009.pdf	286856 a57b70192a2b3f016d5e0994661354e d79b	no	12
Warnings:					
Information:					
13	NPL Documents	10Medhurst_JPharmExpTher_2007.pdf	570693 a652a6de36a381b94de7170aa3eb937452 03bb	no	14
Warnings:					
Information:					
14	NPL Documents	11Medhurst_Pain_2008.pdf	411907 f713cd9b18cf5dd85c5e65a2587a32f76a 376	no	9
Warnings:					
Information:					
15	NPL Documents	12Perez-Garcia_Psychopharmacology_1999.pdf	113685 f029ac4e9e0f7ca93d68c6d60a0e9c07a a2f	no	6
Warnings:					
Information:					

16	NPL Documents	13Fox_JPharmExpTher_2005.pdf	918938 23776d96233d9efbcb42aa26d59229e6 2afc7	no	15
Warnings:					
Information:					
17	NPL Documents	14Wijtmans_ExpOpinionInvestDrugs_2007.pdf	325360 6a6f7361c49062006177982817936-1fd3- 368	no	20
Warnings:					
Information:					
18	NPL Documents	15Celanire_DDT_2005.pdf	361602 e6f93475c4b7990429c-a59901c92e-1fd3- 4fd3b	no	15
Warnings:					
Information:					
19	NPL Documents	16Sander_BioPharmBull_2008.pdf	2446624 b668a5f2a2c6e9d480636f144056117e69 8c31	no	19
Warnings:					
Information:					
20	Fee Worksheet (PTO-875)	fee-info.pdf	30845 7613769d946675a9488c162123d4ef1a 781ef	no	2
Warnings:					
Information:					
Total Files Size (in bytes):				56500522	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111. If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371. If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					